Document is current
Any future updates will be listed below
-
Authors
Burghardt, Isabel
Schroeder, Judith Johanna
Weiss, Tobias
Gramatzki, Dorothee
Weller, Michael https://orcid.org/0000-0002-1748-174X
-
Funding
Funding for this research was provided by:
Swiss Cancer League/Oncosuisse (KFS-3305-08-2013)
Canton Zurich (Highly specialized medicine (HSM-2))
Universität Zürich (Forschungskredit 54251101, Clinical Research Priority Program (CRPP) of the University of Zurich for the CRPP ImmunoCure)
Universität Zürich
- License Information
-
More Information
Article History
Received: 24 June 2020
Accepted: 4 March 2021
First Online: 26 March 2021
Compliance with ethical standards
:
: MW has received research grants from Abbvie, Adastra, Dracen, Merck, Sharp and Dohme (MSD), Merck (EMD) and Novocure, and honoraria for lectures or advisory board participation or consulting from Abbvie, Basilea, Bristol Meyer Squibb (BMS), Celgene, Medac, Merck, Sharp and Dohme (MSD), Merck (EMD), Nerviano Medical Sciences, Orbus, Roche and Tocagen. All other authors declare no conflict of interest.
: The patient data were retrieved in accordance with the appropriate institutional review board following informed consent. The analysis was performed according to the guidelines of the local ethics committees (Kantonale Ethikkommission Zürich, Switzerland, KEK-ZH-Nr./ BASCE-Nr. 2016-00456). Animal experiments were checked and approved, and conducted under valid license and permission of the Cantonal Veterinary Office Zurich and Federal Food Safety and Veterinary Office (Permission Number 80/2013).
